Circulating tumor cells as biomarkers in prostate cancer

Por Danila, Daniel C., Fleisher, Martin, Scher, Howard I.
Publicado em 2011

Circulating Tumors Cells as Biomarkers: Progress Toward Biomarker Qualification

Por Danila, Daniel C., Pantel, Klaus, Fleisher, Martin, Scher, Howard I.
Publicado em 2011

Selective induction of apoptosis by the cytotoxic analog AN-207 in cells expressing recombinant receptor for luteinizing hormone-releasing hormone

Por Danila, Daniel C., Schally, Andrew V., Nagy, Attila, Alexander, Joseph M.
Publicado em 1999

Mutational Analysis of Circulating Tumor Cells Using a Novel Microfluidic Collection Device and qPCR Assay

Por Harb, Wael, Fan, Andrea, Tran, Tony, Danila, Daniel C, Keys, David, Schwartz, Michael, Ionescu-Zanetti, Cristian
Publicado em 2013

Clinical validity of detecting circulating tumor cells by AdnaTest assay compared to direct detection of tumor mRNA in stabilized whole blood, as a biomarker predicting overall sur...

Por Danila, Daniel C., Samoila, Aliaksandra, Patel, Chintan, Schreiber, Nicole, Herkal, Amrita, Anand, Aseem, Bastos, Diogo, Heller, Glenn, Fleisher, Martin, Scher, Howard I.
Publicado no Cancer J (2016)

Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors

Por Mitsiades, Nicholas, Sung, Clifford C., Schultz, Nikolaus, Danila, Daniel C., He, Bin, Eedunuri, Vijay Kumar, Fleisher, Martin, Sander, Chris, Sawyers, Charles L., Scher, Howard I.
Publicado em 2012

Analytical and Clinical Validation of a Prostate Cancer-Enhanced messenger RNA Detection Assay in Whole Blood as a Prognostic Biomarker for Survival

Por Danila, Daniel C., Anand, Aseem, Schultz, Nikolaus, Heller, Glenn, Wan, Mingliang, Sung, Clifford C., Dai, Charles, Khanin, Raya, Fleisher, Martin, Lilja, Hans, Scher, Howard I.
Publicado em 2013

Fluorescence in situ Hybridization Analysis of Circulating Tumor Cells in Metastatic Prostate Cancer

Por Leversha, Margaret A., Han, Jialian, Asgari, Zahra, Danila, Daniel C., Lin, Oscar, Gonzalez-Espinoza, Rita, Anand, Aseem, Lilja, Hans, Heller, Glenn, Fleisher, Martin, Scher, Howard I.
Publicado em 2009

TMPRSS2-ERG Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated With Abiraterone Acetate

Por Danila, Daniel C., Anand, Aseem, Sung, Clifford C., Heller, Glenn, Leversha, Margaret A., Cao, Long, Lilja, Hans, Molina, Arturo, Sawyers, Charles L., Fleisher, Martin, Scher, Howard I.
Publicado em 2011

Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer

Por Scher, Howard I., Graf, Ryon P., Schreiber, Nicole A., McLaughlin, Brigit, Lu, David, Louw, Jessica, Danila, Daniel C., Dugan, Lyndsey, Johnson, Ann, Heller, Glenn, Fleisher, Martin, Dittamore, Ryan
Publicado no Eur Urol (2016)

Repurposing Itraconazole as a Treatment for Advanced Prostate Cancer: A Noncomparative Randomized Phase II Trial in Men With Metastatic Castration-Resistant Prostate Cancer

Por Antonarakis, Emmanuel S., Heath, Elisabeth I., Smith, David C., Rathkopf, Dana, Blackford, Amanda L., Danila, Daniel C., King, Serina, Frost, Anja, Ajiboye, A. Seun, Zhao, Ming, Mendonca, Janet, Kachhap, Sushant K., Rudek, Michelle A., Carducci, Michael A.
Publicado em 2013

Circulating Tumor Cell Biomarker Panel As an Individual-Level Surrogate for Survival in Metastatic Castration-Resistant Prostate Cancer

Por Scher, Howard I., Heller, Glenn, Molina, Arturo, Attard, Gerhardt, Danila, Daniel C., Jia, Xiaoyu, Peng, Weimin, Sandhu, Shahneen K., Olmos, David, Riisnaes, Ruth, McCormack, Robert, Burzykowski, Tomasz, Kheoh, Thian, Fleisher, Martin, Buyse, Marc, de Bono, Johann S.
Publicado no J Clin Oncol (2015)

Severe Hypocalcemia Associated With Denosumab in Metastatic Castration-Resistant Prostate Cancer: Risk Factors and Precautions for Treating Physicians

Por Autio, Karen A., Farooki, Azeez, Glezerman, Ilya G., Chan, Amelia, Schneider, Coursen W., Barr, Hallie C., Seyboth, Brian M., Kampel, Lewis J., Danila, Daniel C., Rathkopf, Dana E., Slovin, Susan F., Scher, Howard I., Morris, Michael J.
Publicado no Clin Genitourin Cancer (2014)

Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer

Por Rathkopf, Dana E., Morris, Michael J., Fox, Josef J., Danila, Daniel C., Slovin, Susan F., Hager, Jeffrey H., Rix, Peter J., Chow Maneval, Edna, Chen, Isan, Gönen, Mithat, Fleisher, Martin, Larson, Steven M., Sawyers, Charles L., Scher, Howard I.
Publicado em 2013

Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer

Por Scher, Howard I., Lu, David, Schreiber, Nicole A., Louw, Jessica, Graf, Ryon P., Vargas, Hebert A., Johnson, Ann, Jendrisak, Adam, Bambury, Richard, Danila, Daniel, McLaughlin, Brigit, Wahl, Justin, Greene, Stephanie B., Heller, Glenn, Marrinucci, Dena, Fleisher, Martin, Dittamore, Ryan
Publicado no JAMA Oncol (2016)

Circulating prostate tumor cells detected by RT-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone meta...

Por Helo, Pauliina, Cronin, Angel M., Danila, Daniel C., Wenske, Sven, Gonzalez-Espinoza, Rita, Anand, Aseem, Väänänen, Riina-Minna, Pettersson, Kim, Chun, Felix K.-H., Steuber, Thomas, Huland, Hartwig, Guillonneau, Bertrand D, Eastham, James A., Scardino, Peter T., Fleisher, Martin, Scher, Howard I., Lilja, Hans
Publicado em 2009

Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer

Por Lorente, David, Olmos, David, Mateo, Joaquin, Bianchini, Diletta, Seed, George, Fleisher, Martin, Danila, Daniel C., Flohr, Penny, Crespo, Mateus, Figueiredo, Ines, Miranda, Susana, Baeten, Kurt, Molina, Arturo, Kheoh, Thian, McCormack, Robert, Terstappen, Leon W.M.M., Scher, Howard I., de Bono, Johann S.
Publicado no Eur Urol (2016)

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

Por Scher, Howard I, Beer, Tomasz M, Higano, Celestia S, Anand, Aseem, Taplin, Mary-Ellen, Efstathiou, Eleni, Rathkopf, Dana, Shelkey, Julia, Yu, Evan Y, Alumkal, Joshi, Hung, David, Hirmand, Mohammad, Seely, Lynn, Morris, Michael J, Danila, Daniel C, Humm, John, Larson, Steve, Fleisher, Martin, Sawyers, Charles L
Publicado em 2010

Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer

Por Danila, Daniel C., Morris, Michael J., de Bono, Johann S., Ryan, Charles J., Denmeade, Samuel R., Smith, Matthew R., Taplin, Mary-Ellen, Bubley, Glenn J., Kheoh, Thian, Haqq, Christopher, Molina, Arturo, Anand, Aseem, Koscuiszka, Michael, Larson, Steve M., Schwartz, Lawrence H., Fleisher, Martin, Scher, Howard I.
Publicado em 2010

Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study

Por Olmos, David, Brewer, Daniel, Clark, Jeremy, Danila, Daniel C, Parker, Chris, Attard, Gerhardt, Fleisher, Martin, Reid, Alison H M, Castro, Elena, Sandhu, Shahneen K, Barwell, Lorraine, Oommen, Nikhil Babu, Carreira, Suzanne, Drake, Charles G, Jones, Robert, Cooper, Colin S, Scher, Howard I, de Bono, Johann S
Publicado no Lancet Oncol (2012)